The FDA has approved an injectable formulation of Merck’s cancer immunotherapy Keytruda (Qlex), reducing administration time to minutes compared to the conventional infusion which takes around 30 minutes. Clinical trials demonstrated comparable safety and efficacy profiles between the injectable and infused versions. This approval is anticipated to enhance patient convenience and clinical workflow in oncology settings, sustaining Keytruda’s position as a leading immuno-oncology agent.